March 28th 2024
Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
FDA grants priority review for dupilumab in pediatric AD
January 31st 2020The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.
Differences underlie pathology, indicating efficacy of atopic dermatitis treatments may vary
October 10th 2019Atopic dermatitis presents differently depending on whether the patient is an adult or child. This means that different treatments may be more effective in an adult than children and vice versa.
Steroid-free atopic dermatitis topical completes phase 4 trial
July 2nd 2019Crisaborole ointment, 2%, (Eucrisa, Pfizer) appears to be safe and effective in children aged three months to less than 24 months who have mild-to-moderate atopic dermatitis, according to results of a phase 4 trial released yesterday.
Current thinking on acne management
June 4th 2019Traditional treatments remain important parts of the dermatologist's armamentarium for acne management, but other drugs have begun to play a role, too. Meanwhile, research is offering new insight into the causes of acne. Stay up to date on the latest insight into acne's pathogenesis, evaluation and treatment. Participate in this forum.
A game-changer for children with atopic dermatitis
April 26th 2019“Pretty much, I couldn’t go about my normal life,” says Benjamin Sun about a life-altering eczema flare up at age 9, which left him out of school and bedridden for weeks. Until now, children like Sun didn’t have an effective, safe option for long-term disease control. Read how dupilumab changed his quality of life, and what it can do for your pediatric patients with uncontrolled moderate to severe atopic dermatitis.